Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Yuemin Gong, Lina Zhang, Zunmin Zhu, Jianda Hu, Zenghua Lin, Wenwei Zhu, Fangqiong Li, Guangsheng He

Blood (2025) 146 (Supplement 1): 4969.

https://doi.org/10.1182/blood-2025-4969

Published: 2025

Journal Articles

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

Lefu Huang, Yuechen Zhang, Huijuan Wang, Wenjing Li, Yanru Zhang, Menghan Liu, Ying Tian, Zunmin Zhu, Hong-Hu Zhu, Wenming Chen, Aijun Liu

Blood (2025) 146 (Supplement 1): 7576.

https://doi.org/10.1182/blood-2025-7576

Published: 2025

Journal Articles

Integrating the cardiovascular-renal-metabolic syndrome（ckm）: Construction and validation of a comprehensive model for early identification of high-risk multiple myeloma

Xiaoman Sun, Menghao Wei, Min Song, Ning Liu, Zhenxing Gao, Wenyi Lu, Zunmin Zhu, Jie Shi

Blood (2025) 146 (Supplement 1): 2796.

https://doi.org/10.1182/blood-2025-2796

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

From fit to frail: Effectiveness and safety of fixed-dose carfilzomib in the treatment of multiple myeloma – a single-center, real world evidence in China

Menghao Wei, Xiaoman Sun, Min Song, Ning Liu, Wenyi Lu, Zunmin Zhu, Jie Shi

Blood (2025) 146 (Supplement 1): 7506.

https://doi.org/10.1182/blood-2025-7506

Published: 2025

Journal Articles

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Blood (2025) 146 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2025-1902

Published: 2025

Journal Articles

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5245.

https://doi.org/10.1182/blood-2025-5245

Published: 2025

Journal Articles

Dual-armoring of CLL-1 CAR-T cells with IL-18 and an RQR8 suicide switch enhances efficacy and safety in Acute Myeloid Leukemia

Wenyi Lu, Bing Cao, Xin Jin, Yuanyuan Hao, Lei Zhang, Wei Cheng, Wei Li, Zhenxin Zhao, Zhoufeng Huang, Wenyan Li, Yuanbo Liu, Mingfeng Zhao, Zunmin Zhu

Blood (2025) 146 (Supplement 1): 4124.

https://doi.org/10.1182/blood-2025-4124

Published: 2025

Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2025-5677

Published: 2025

Journal Articles

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Blood (2025) 146 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2025-1878

Published: 2025

Journal Articles

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Blood (2024) 144 (Supplement 1): 2187.

https://doi.org/10.1182/blood-2024-206919

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

Gender Influences Clinical Characteristics of Classical Ph Negative Myeloproliferative Neoplasms

Yanan Cai, Yuebo Wang, Wenyi Lu, Ping Zhang, Zunmin Zhu

Blood (2024) 144 (Supplement 1): 6670.

https://doi.org/10.1182/blood-2024-203385

Published: 2024

Journal Articles

Gender Influences Epidemiologic Characteristics of Secondary Malignant Neoplasms in Classical Ph Negative Myeloproliferative Neoplasms

Yanan Cai, Yuebo Wang, Wenyi Lu, Ping Zhang, Zunmin Zhu

Blood (2024) 144 (Supplement 1): 6667.

https://doi.org/10.1182/blood-2024-201981

Published: 2024

Journal Articles

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

Blood (2024) 144 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2024-212216

Published: 2024

Journal Articles

DCAF13 Is Essential for Hematopoietic Stem Cell Function By Stabilization of Ribosome Biogenesis and P53 Pathway

Mengke Li, Yuxin Wu, Qing Zhang, Shuai Zhou, Rui Zhang, Shengnan Yuan, YingYing Wang, Huan Zhao, Wenyi Lu, Xiaojing Shi, Dongping Wei, Zunmin Zhu, Song Chen

Blood (2024) 144 (Supplement 1): 2651.

https://doi.org/10.1182/blood-2024-198288

Published: 2024

Journal Articles

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Rong Fu, Hong Yu, Aijun Liu, Rui Hou, Zunmin Zhu, Junling Zhuang, Li Bao, Zhenling Li, Lihong Liu, Luoming Hua, Yanping Ma, Da Gao, ARong Jin, Xiaohui Suo, Wei Yang, Yuansong Bai, Deqiang Zheng, Wenming Chen

Blood (2024) 144 (Supplement 1): 7846.

https://doi.org/10.1182/blood-2024-209471

Published: 2024

Journal Articles

Homoharringtonine Combining with Azacitidine and Venetoclax (HAV) As First-Line Induction Therapy for Newly Diagnosed Adult Acute Myeloid Leukemia Patients

Wenyi Lu, Xiangli Chen, Yuzhu Zang, Zunmin Zhu, Wenhui Zhang, Yanliang Bai, Yuqing Chen, Li Jiang, Yanyan Xing, Yuanbo Liu, Jie Shi, Zhenxing Gao

Blood (2024) 144 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2024-203408

Published: 2024

Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2023-179073

Published: 2023

Journal Articles

Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib

Blood (2023) 142 (Supplement 1): 3171.

https://doi.org/10.1182/blood-2023-179142

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

Integrating the cardiovascular-renal-metabolic syndrome（ckm）: Construction and validation of a comprehensive model for early identification of high-risk multiple myeloma

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

From fit to frail: Effectiveness and safety of fixed-dose carfilzomib in the treatment of multiple myeloma – a single-center, real world evidence in China

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

Dual-armoring of CLL-1 CAR-T cells with IL-18 and an RQR8 suicide switch enhances efficacy and safety in Acute Myeloid Leukemia

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Gender Influences Clinical Characteristics of Classical Ph Negative Myeloproliferative Neoplasms

Gender Influences Epidemiologic Characteristics of Secondary Malignant Neoplasms in Classical Ph Negative Myeloproliferative Neoplasms

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

DCAF13 Is Essential for Hematopoietic Stem Cell Function By Stabilization of Ribosome Biogenesis and P53 Pathway

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Homoharringtonine Combining with Azacitidine and Venetoclax (HAV) As First-Line Induction Therapy for Newly Diagnosed Adult Acute Myeloid Leukemia Patients

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only